Leading global law firm Baker McKenzie has advised private equity firm H.I.G. Capital and its portfolio company, Vernacare, on the financing for their acquisition of the Infection Prevention business from Frontier Medical Group (who are backed by Kester Capital). The transaction will include the industry leading brands Sharpsafe®, Clinisafe® and eXchange™ which provide an extensive range of clinical sharps and waste disposal solutions.

James Mitchell, Principal at H.I.G. Capital in London, commented, “The Frontier Infection Prevention business is a growing industry leader in the manufacture and supply of products that contain and dispose of infectious material safely – critical systems in protecting the Healthcare workforce and limiting the spread of infection. H.I.G. is looking forward to working with Frontier Medical’s Infection Prevention business, which is highly complementary to Vernacare’s existing presence in the clinical Infection Prevention sector. We believe the combination will strengthen Vernacare’s market position and support an ambitious organic growth strategy; we will also continue to pursue similar accretive acquisitions in the sector across the UK and internationally over the coming years”.

James Steele, Chief Executive of Vernacare, added, “Frontier’s Infection Prevention business and Vernacare fit very well together with a common focus on best practice within Infection Prevention, and together, will be even better placed to help improve Infection Prevention standards within UK and overseas healthcare systems’’

Leading the Baker McKenzie team on the transaction, London partner Nick O’Grady said, “It has been fantastic to support H.I.G. Capital and Vernacare on this very important and high profile transaction. At a time when the healthcare industry is playing such a critical role in the nation’s welfare we are very pleased to help grow this market-leading business in the Infection Prevention sector."

The Baker McKenzie team was led from London by Banking and Finance partner Nick O’Grady and supported by Connor Lovie (associate) Kristin Gottschalk (trainee) and Matthew Cox (partner).

The Vernacare acquisition of the Infection Prevention businesses from Frontier Medical Group is another example of Baker McKenzie’s market-leading transactional practice group and healthcare expertise. Other recent transactions include representing GSK on its transformational joint venture with Pfizer's Consumer Healthcare business to create the world's largest over the counter healthcare business with combined sales of approximately USD 12.7 billion. As well as GSK's strategically significant sale of its two global travel vaccines businesses for approximately USD 1 billion.
Explore Our Newsroom